ACTL6A: unraveling its prognostic impact and paving the way for targeted therapeutics in carcinogenesis.

Autor:	Eid RA; Pathology Department, College of Medicine, King Khalid University, Abha, Saudi Arabia., Mamdouh F; Biotechnology Division, Zoology Department, Faculty of Science, Benha University, Banha, Egypt., Abdulsahib WK; Pharmacology and Toxicology Department, College of Pharmacy, Al Farahidi University, Baghdad, Iraq., Alshaya DS; Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia., Al-Salmi FA; Biology Department, College of Sciences, Taif University, Taif, Saudi Arabia., Ali Alghamdi M; Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia., Jafri I; Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia., Fayad E; Department of Biotechnology, College of Sciences, Taif University, Taif, Saudi Arabia., Alsharif G; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.; Department of Biomedical Research, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia., Zaki MSA; Anatomy Department, College of Medicine, King Khalid University, Abha, Saudi Arabia., Alshehri MA; Department of Child Health, College of Medicine, King Khalid University, Abha, Saudi Arabia., Noreldin AE; Department of Histology and Cytology, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt., Alaa Eldeen M; Cell Biology, Histology and Genetics Division, Zoology Department, Faculty of Science, Zagazig University, Zagazig, Egypt.
Jazyk:	angličtina
Zdroj:	Frontiers in molecular biosciences [Front Mol Biosci] 2024 May 30; Vol. 11, pp. 1387919. Date of Electronic Publication: 2024 May 30 (Print Publication: 2024).
DOI:	10.3389/fmolb.2024.1387919
Abstrakt:	Introduction: Increased Actin-like 6A (ACTL6A) expression is associated with various cancers, but its comprehensive investigation across different malignancies is lacking. We aimed to analyze ACTL6A as a potential oncogene and therapeutic target using bioinformatics tools. Methods: We comprehensively analyzed ACTL6A expression profiles across human malignancies, focusing on correlations with tumor grade, stage, metastasis, and patient survival. Genetic alterations were examined, and the epigenetic landscape of ACTL6A was assessed using rigorous methods. The impact of ACTL6A on immune cell infiltration in the tumor microenvironment was evaluated, along with molecular docking studies and machine learning models. Results: Our analysis revealed elevated ACTL6A expression in various tumors, correlating with poor prognostic indicators such as tumor grade, stage, metastasis, and patient survival. Genetic mutations and epigenetic modifications were identified, along with associations with immune cell infiltration and key cellular pathways. Machine learning models demonstrated ACTL6A's potential for cancer detection. Discussion: ACTL6A emerges as a promising diagnostic and therapeutic target in cancer, with implications for prognosis and therapy. Our study provides comprehensive insights into its carcinogenic actions, highlighting its potential as both a prognostic indicator and a target for anti-cancer therapy. This integrative approach enhances our understanding of ACTL6A's role in cancer pathogenesis and treatment. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Eid, Mamdouh, Abdulsahib, Alshaya, Al-Salmi, Ali Alghamdi, Jafri, Fayad, Alsharif, Zaki, Alshehri, Noreldin and Alaa Eldeen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu